Perceptive Advisors LLC
- SEC CIK
- 0001224962
- Latest filing
- Aug 14, 2026
Holdings in Q1 2022
Holdings as of Mar 31, 2022, filed May 16, 2022. Long positions only; changes compare share counts with Q4 2021.
- Positions
- 135
- −10 vs. Q4 2021
- Portfolio value
- $4.81B
- −$1.66B (−25.6%) vs. Q4 2021
| Security | Class | Shares | Value | % of portfolio | Share change | Action | History |
|---|---|---|---|---|---|---|---|
| BBIOBridgeBio Pharma, Inc. | COM | 3,839,380 | $39.0M | 0.8% | −3,289,375−46.1% | Reduced | History |
| NAUTNautilus Biotechnology, Inc. | COM | 9,111,151 | $39.5M | 0.8% | 00.0% | Unchanged | History |
| INBXInhibrx Biosciences, Inc. | COM | 1,781,235 | $39.7M | 0.8% | +437,745+32.6% | Added | History |
| CINCCinCor Pharma, Inc. | COM | 2,319,117 | $40.7M | 0.8% | +2,319,117 | New | History |
| ChemoCentryx, Inc.16383L106 | COM | 1,655,079 | $41.5M | 0.9% | +239,633+16.9% | Added | – |
| ALDXAldeyra Therapeutics, Inc. | COM | 9,903,879 | $44.0M | 0.9% | 00.0% | Unchanged | History |
| Coherus Biosciences Inc19249HAB9 | NOTE 1.500% 4/1 | – | $44.6M | 0.9% | – | – | – |
| LONALeonaBio, Inc. | COM | 3,425,916 | $46.3M | 1.0% | 00.0% | Unchanged | History |
| TVTXTravere Therapeutics, Inc. | COM | 1,845,555 | $47.6M | 1.0% | 00.0% | Unchanged | History |
| CCCCC4 Therapeutics, Inc. | COM STK | 2,082,723 | $50.5M | 1.0% | −126,190−5.7% | Reduced | History |
| PRCTPROCEPT BioRobotics Corp | COM | 1,488,284 | $52.1M | 1.1% | +159,999+12.0% | Added | History |
| Bellus Health Inc New07987C204 | COM NEW | 8,136,630 | $56.0M | 1.2% | +491,396+6.4% | Added | – |
| RLAYRelay Therapeutics, Inc. | COM | 1,943,097 | $58.2M | 1.2% | 00.0% | Unchanged | History |
| CHRSCoherus Oncology, Inc. | COM | 4,695,848 | $60.6M | 1.3% | −711,950−13.2% | Reduced | History |
| RAPTRAPT Therapeutics, Inc. | COM | 2,799,962 | $61.6M | 1.3% | −127,603−4.4% | Reduced | History |
| ALBOAlbireo Pharma, Inc. | COM | 2,360,139 | $70.4M | 1.5% | 00.0% | Unchanged | History |
| XENEXenon Pharmaceuticals Inc. | COM | 2,411,447 | $73.7M | 1.5% | 00.0% | Unchanged | History |
| APLSApellis Pharmaceuticals, Inc. | COM | 1,481,700 | $75.3M | 1.6% | +30,000+2.1% | Added | History |
| OMOutset Medical, Inc. | COM | 1,883,399 | $85.5M | 1.8% | +20,002+1.1% | Added | History |
| VBIVVBI Vaccines Inc/BC | COM NEW | 52,335,002 | $86.9M | 1.8% | 00.0% | Unchanged | History |
| ISEEIVERIC bio, Inc. | COM | 5,225,415 | $87.9M | 1.8% | −1,254,585−19.4% | Reduced | History |
| Collegium Pharmaceutical, Inc19459JAA2 | NOTE 2.625% 2/1 | – | $89.5M | 1.9% | – | – | – |
| RXDXPrometheus Biosciences, Inc. | COM | 2,440,582 | $92.2M | 1.9% | −732,203−23.1% | Reduced | History |
| MGTXMeiraGTx Holdings plc | COM | 6,948,277 | $96.2M | 2.0% | 00.0% | Unchanged | History |
| CRNXCrinetics Pharmaceuticals, Inc. | COM | 5,163,517 | $113.3M | 2.4% | 00.0% | Unchanged | History |
| GBTGlobal Blood Therapeutics, Inc. | COM | 3,892,493 | $134.8M | 2.8% | +442,578+12.8% | Added | History |
| HZNPHorizon Therapeutics Public Ltd Co | SHS | 1,357,903 | $142.9M | 3.0% | −380,237−21.9% | Reduced | History |
| CERECerevel Therapeutics Holdings, Inc. | COM | 5,086,727 | $178.1M | 3.7% | 00.0% | Unchanged | History |
| MRTXMirati Therapeutics, Inc. | COM | 2,380,710 | $195.7M | 4.1% | −903,073−27.5% | Reduced | History |
| IOVAIovance Biotherapeutics, Inc. | COM | 12,201,261 | $203.2M | 4.2% | +2,073,320+20.5% | Added | History |
| LIANYLianBio | SPONSORED ADS | 56,319,960 | $208.9M | 4.3% | 00.0% | Unchanged | History |
| SWTXSpringWorks Therapeutics, Inc. | COM | 4,527,993 | $255.6M | 5.3% | −321,919−6.6% | Reduced | History |
| FOLDAmicus Therapeutics, Inc. | COM | 27,555,845 | $261.0M | 5.4% | +996,402+3.8% | Added | History |
| Travere Therapeutics, Inc.89422GAA5 | NOTE 2.250% 3/0 | – | $474.1M | 9.8% | – | New | – |
| AGRXAgile Therapeutics Inc | COM | 21,294,485 | – | – | 00.0% | Unchanged | History |
Sold out since Q4 2021 (24)
Positions held at the end of Q4 2021 that are gone from this filing.
| Security | Class | Shares in Q4 2021 | Value in Q4 2021 | % of portfolio in Q4 2021 | History |
|---|---|---|---|---|---|
| Retrophin Inc761299AB2 | NOTE 2.500% 9/1 | – | $484.7M | 7.5% | – |
| BMRNBiomarin Pharmaceutical Inc | COM | 1,180,000 | $104.3M | 1.6% | History |
| Nevro Corp64157FAC7 | NOTE 2.750% 4/0 | – | $101.5M | 1.6% | – |
| ARNAArena Pharmaceuticals Inc | COM NEW | 500,000 | $46.5M | 0.7% | History |
| KODKodiak Sciences Inc. | COM | 520,152 | $44.1M | 0.7% | History |
| UTHRUnited Therapeutics Corp | COM | 94,064 | $20.3M | 0.3% | History |
| VTRSViatris Inc | Stock | 1,004,419 | $13.6M | 0.2% | History |
| BCABBioAtla, Inc. | COM | 661,200 | $13.0M | 0.2% | History |
| IMCRImmunocore Holdings plc | ADS | 360,000 | $12.3M | 0.2% | History |
| BIIBBiogen Inc. | COM | 48,600 | $11.7M | 0.2% | History |
| HRMYHarmony Biosciences Holdings, Inc. | COM | 239,258 | $10.2M | 0.2% | History |
| ADPTAdaptive Biotechnologies Corp | COM | 352,804 | $9.90M | 0.2% | History |
| KYMRKymera Therapeutics, Inc. | COM | 155,000 | $9.84M | 0.2% | History |
| ONEM1Life Healthcare Inc | COM | 532,350 | $9.35M | 0.1% | History |
| CLDXCelldex Therapeutics, Inc. | COM NEW | 229,807 | $8.88M | 0.1% | History |
| EQRXEQRx, Inc. | COM | 1,250,000 | $8.53M | 0.1% | History |
| TBIOTelesis Bio Inc. | COM | 425,000 | $4.59M | 0.1% | History |
| Achilles Therapeutics PLC00449L102 | SPONSORED ADS | 755,375 | $3.78M | 0.1% | – |
| AXSMAxsome Therapeutics, Inc. | COM | 80,420 | $3.04M | <0.1% | History |
| PMVPPMV Pharmaceuticals, Inc. | COM | 125,000 | $2.89M | <0.1% | History |
| YARWYarrow Bioscience, Inc. | COM | 2,178,022 | $2.22M | <0.1% | History |
| ITOSiTeos Therapeutics, Inc. | COM | 20,000 | $931.0K | <0.1% | History |
| EIGREiger BioPharmaceuticals, Inc. | COM | 139,890 | $726.0K | <0.1% | History |
| PHVSPharvaris N.V. | COM | 27,000 | $389.0K | <0.1% | History |